Sarilumab

Sarilumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target IL6
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 1189541-98-7 N
ATC code None
Chemical data
Formula C6388H9918N1718O1998S44 
Mol. mass 144.13 kDa
 N(what is this?)  (verify)

Sarilumab is a human monoclonal antibody designed for the treatment of rheumatoid arthritis and ankylosing spondylitis.[1]

Sarilumab was developed by Regeneron Pharmaceuticals, Inc.

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/sarilumab.pdf. 
Immune system ("-l(i[m])-")
Human ("-limu-")
Mouse ("-limo-")
Chimeric ("-lixi-")
Humanized ("-lizu-")
Chimeric + humanized
("-lixizu-")
Interleukin ("-k(i[n])-")
Human ("-kinu-")
Humanized ("-kizu-", "-kinzu-")
Inflammatory lesions ("-les-")
Mouse ("-leso-")

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug(L3/4)